ALX Oncology Holdings Inc. (NASDAQ:ALXO) Given Consensus Rating of “Moderate Buy” by Brokerages

ALX Oncology Holdings Inc. (NASDAQ:ALXO) has earned a consensus recommendation of “Moderate Buy” from the seven research firms that are covering the firm, MarketBeat Ratings reports. One analyst has rated the stock with a sell recommendation, one has given a hold recommendation and five have issued a buy recommendation on the company. The average 12-month price objective among analysts that have issued ratings on the stock in the last year is $3.50.

Several equities analysts recently weighed in on ALXO shares. Jefferies Financial Group started coverage on shares of ALX Oncology in a report on Thursday, November 13th. They issued a “buy” rating and a $4.00 price objective on the stock. Weiss Ratings reiterated a “sell (d-)” rating on shares of ALX Oncology in a research report on Wednesday, October 8th. Finally, Wall Street Zen upgraded ALX Oncology from a “sell” rating to a “hold” rating in a research report on Saturday.

Insider Transactions at ALX Oncology

In related news, CEO Jason Lettmann bought 71,163 shares of the firm’s stock in a transaction dated Wednesday, September 17th. The stock was bought at an average cost of $1.08 per share, for a total transaction of $76,856.04. Following the transaction, the chief executive officer owned 305,121 shares of the company’s stock, valued at $329,530.68. This represents a 30.42% increase in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available at this hyperlink. Company insiders own 21.00% of the company’s stock.

Institutional Inflows and Outflows

Several hedge funds and other institutional investors have recently bought and sold shares of the company. Ameriprise Financial Inc. bought a new stake in ALX Oncology in the third quarter valued at approximately $1,195,000. Jane Street Group LLC bought a new stake in shares of ALX Oncology in the 2nd quarter valued at $84,000. Acadian Asset Management LLC raised its stake in ALX Oncology by 16.8% during the 1st quarter. Acadian Asset Management LLC now owns 1,296,331 shares of the company’s stock worth $806,000 after buying an additional 186,883 shares during the period. Nuveen LLC bought a new position in ALX Oncology during the first quarter worth about $103,000. Finally, Almitas Capital LLC grew its stake in ALX Oncology by 10.6% in the first quarter. Almitas Capital LLC now owns 1,353,141 shares of the company’s stock valued at $843,000 after acquiring an additional 130,196 shares during the period. Institutional investors own 97.97% of the company’s stock.

ALX Oncology Price Performance

ALX Oncology stock opened at $1.42 on Monday. The business’s 50-day simple moving average is $1.56 and its 200 day simple moving average is $1.02. The company has a quick ratio of 2.40, a current ratio of 2.40 and a debt-to-equity ratio of 0.13. The stock has a market cap of $76.99 million, a price-to-earnings ratio of -0.70 and a beta of 0.53. ALX Oncology has a 12-month low of $0.40 and a 12-month high of $2.27.

ALX Oncology (NASDAQ:ALXO) last released its earnings results on Friday, November 7th. The company reported ($0.41) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.37) by ($0.04). As a group, research analysts anticipate that ALX Oncology will post -2.76 earnings per share for the current year.

About ALX Oncology

ALX Oncology Holdings Inc, a clinical-stage immuno-oncology company, focuses on developing therapies for cancer patients in the United States. The company's lead product candidate is Evorpacept, a CD47 blocking therapeutic biologic in development as a combination therapy with other anti-cancer agents, including ASPEN-06, under Phase 2 clinical study for treating Gastric/GEJ cancer; ASPEN-07, under Phase 1 clinical study for treating urothelial cancer; and ASPEN-03 and ASPEN-04, both under Phase 2 clinical study for treating head and neck squamous cell carcinoma.